Get the Stockscreener App
25.46
2.09%
0.52
After Hours:
25.46
Bridgebio Pharma Inc stock is traded at $25.46, with a volume of 1.58M.
It is up +2.09% in the last 24 hours and down -8.58% over the past month.
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
See More
Previous Close:
$24.94
Open:
$24.79
24h Volume:
1.58M
Relative Volume:
0.82
Market Cap:
$4.76B
Revenue:
$218.60M
Net Income/Loss:
$-538.26M
P/E Ratio:
-6.5282
EPS:
-3.9
Net Cash Flow:
$-605.72M
1W Performance:
+0.24%
1M Performance:
-8.58%
6M Performance:
-17.66%
1Y Performance:
-3.45%
1-Day Range:
$24.79
$26.15
1-Week Range:
$23.86
$26.15
52-Week Range:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - Yahoo Finance
Early-Stage Biotech BridgeBio's Acoramidis Drives Valuation for Long-Term Investors - Morningstar
Transthyretin Amyloid Cardiomyopathy Market Size, Share, - openPR
BridgeBio completes enrollment for potential LGMD2I therapy - Investing.com
BridgeBio Completes Enrollment of FORTIFY, Phase 3 - GlobeNewswire
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) - StockTitan
Perceptive Advisors LLC Trims Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stake Boosted by Frazier Life Sciences Management L.P. - MarketBeat
(BBIO) Investment Report - Stock Traders Daily
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, - GlobeNewswire
Lion Point Capital LP Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Epidermolysis Bullosa Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem - Barchart
Hypoparathyroidism Pipeline Drugs Analysis Report, 2024: FDA - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Federated Hermes Inc. - MarketBeat
Check Out What Whales Are Doing With BBIO - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 3.3% - MarketBeat
BridgeBio Pharma Target of Unusually Large Options Trading (NASDAQ:BBIO) - MarketBeat
Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Simply Wall St
Ensign Peak Advisors Inc Grows Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Has $15.15 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
American Century Companies Inc. Has $27.78 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
First Week of January 2027 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
FDA Grants Breakthrough Status to Achondroplasia Drug - Investing.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $26.19 - MarketBeat
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com Canada
FDA Grants Breakthrough Status to Achondroplasia Drug - Investing.com India
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com UK
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA - GlobeNewswire
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA - StockTitan
BridgeBio stock could see upside as gene therapy BBP-812 earns expedited FDA review - Investing.com Canada
Daiwa Securities Group Inc. Raises Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Victory Capital Management Inc. Acquires 34,360 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 2.2% - MarketBeat
Q3 2024 Earnings Estimate for BridgeBio Pharma, Inc. Issued By Leerink Partnrs (NASDAQ:BBIO) - MarketBeat
Hypoparathyroidism Market Growth Anticipated by 2034 | Companies includes Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics - Barchart
Health Care Up on Cyclical Bias -- Health Care Roundup - Marketscreener.com
Health Care Up on Cyclical Bias -- Health Care Roundup - MarketWatch
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly - The Wall Street Journal
BridgeBio Pharma’s (BBIO) Buy Rating Reaffirmed at Bank of America - Defense World
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down to $29.99 - MarketBeat
BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine - BioPharma Dive
BridgeBio Pharma drops gene therapy program for AAV | Biotechnology | The Pharmaletter - The Pharma Letter
BridgeBio stock slides on discontinuation of CAH gene therapy (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (NASDAQ:BBIO) Given Buy Rating at Bank of America - MarketBeat
BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine - Yahoo Finance
FDA grants RMAT status to BridgeBio's Canavan disease therapy By Investing.com - Investing.com Australia
FDA grants RMAT status to BridgeBio's Canavan disease therapy - Investing.com India
BridgeBio Pharma Reports Topline Results from Phase 1/2 - GlobeNewswire
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):